Osaic Holdings
KLRS

Osaic Holdings’s Kalaris Therapeutics KLRS Stock Holding History

Osaic Holdings’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-161
Closed -$1.55K – 7786
2024
Q4 		$1.55K Sell
161
-652
-80% -$9.86K ﹤0.01% 6704
2024
Q3 		$15.1K Buy
813
+161
+25% +$2.82K ﹤0.01% 5545
2024
Q2 		$10.8K Hold
652
– – ﹤0.01% 5737
2024
Q1 		$11.3K Hold
652
– – ﹤0.01% 5686
2023
Q4 		$10.2K Hold
652
– – ﹤0.01% 5820
2023
Q3 		$32.3K Buy
+652
New +$44.4K ﹤0.01% 5276
2023
Q2 		– Sell
-1,030
Closed -$93.3K – 7604
2023
Q1 		$93.3K Buy
1,030
+2
+0.2% +$255 ﹤0.01% 4509
2022
Q4 		$121K Hold
1,028
– – ﹤0.01% 4283
2022
Q3 		$187K Hold
1,028
– – ﹤0.01% 3812
2022
Q2 		$92K Hold
1,028
– – ﹤0.01% 4492
2022
Q1 		$160K Hold
1,028
– – ﹤0.01% 4210
2021
Q4 		$306K Sell
1,028
-56
-5% -$26K ﹤0.01% 3549
2021
Q3 		$625K Hold
1,084
– – ﹤0.01% 2807
2021
Q2 		$492K Hold
1,084
– – ﹤0.01% 3048
2021
Q1 		$584K Buy
+1,084
New +$911K ﹤0.01% 2718

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings's KLRS Position: Q1 2025 in Review

Osaic Holdings sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 161 shares — an estimated $1.55K sold.

Osaic Holdings first reported a position in KLRS in Q1 2021 and held it in 15 quarters. The position peaked at $625K in Q3 2021. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • Osaic Holdings reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Osaic Holdings sold 161 Kalaris Therapeutics shares in Q1 2025, an estimated $1.55K.
  • Osaic Holdings first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 15 quarters.
  • Osaic Holdings's Kalaris Therapeutics position peaked at $625K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on Osaic Holdings's 13F filing for Q1 2025, filed 12 May 2025.